The FDA officially rescinded its recent final rule governing laboratory-developed tests (LDTs), restoring the regulatory framework to prior standards that did not explicitly grant FDA authority over LDTs. This decision follows industry and stakeholder challenges concerning oversight scope and burdens. The repeal reflects ongoing debates about appropriate regulation balancing innovation, patient safety, and market access in in vitro diagnostics. The change affects diagnostic developers and clinical laboratories significantly.